FDA withdraws coronavirus emergency use authorization for hydroxychloroquine


A free daily digest of the biggest news stories of the day - and the best features from our website
Thank you for signing up to TheWeek. You will receive a verification email shortly.
There was a problem. Please refresh the page and try again.
At the request of Gary Disbrow, the acting director of the Biomedical Advanced Research and Development Authority, the Food and Drug Administration on Monday withdrew emergency use authorizations for hydroxychloroquine and chloroquine related to coronavirus treatment.
The authorizations were controversial, as many skeptics believed they were made because President Trump had touted the malaria drugs as effective treatments against COVID-19, despite researchers concerns about potential heart-related side effects. Ultimately, after reviewing new information from large clinical trials, the FDA said it does not believe the drugs are likely "to produce an antiviral effect" against the novel virus.
Hydroxychloroquine is approved for several uses like treating arthritis and lupus, so doctors could still use it "off label" to treat coronavirus patients, and clinical trials examining its effect against COVID-19 can continue, Politico reports. The version of chloroquine temporarily authorized by the FDA, however, is not approved in the U.S., so all use of it will end. Read more at Politico.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
Sign up to our 10 Things You Need to Know Today newsletter
A free daily digest of the biggest news stories of the day - and the best features from our website
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
More than 2,000 dead following massive earthquake in Morocco
Speed Read
By Justin Klawans Published
-
Mexico's next president will almost certainly be its 1st female president
Speed Read
By Peter Weber Published
-
North Korea's Kim to visit Putin in eastern Russia to discuss arms sales for Ukraine war, U.S. says
Speed Read
By Peter Weber Published
-
Gabon's military leader sworn in following coup in latest African uprising
Speed Read
By Justin Klawans Published
-
Nobody seems surprised Wagner's Prigozhin died under suspicious circumstances
Speed Read
By Peter Weber Published
-
Western mountain climbers allegedly left Pakistani porter to die on K2
Speed Read
By Justin Klawans Published
-
'Circular saw blades' divide controversial Rio Grande buoys installed by Texas governor
Speed Read
By Peter Weber Published
-
Los Angeles city workers stage 1-day walkout over labor conditions
Speed Read
By Justin Klawans Published